Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment. Although patients with mild to moderate psoriatic arthritis may be treated with nonsteroidal anti-inflammatory drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant psoriatic arthritis. We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis. (J Am Acad Dermatol 2008;58:851-64.)

DISCLAIMER

Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines do not purport to establish a legal standard of care and should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient.
METHOD

A work group of recognized experts was convened to determine the audience for the guideline, define the scope of the guideline, and identify clinical questions to structure the primary issues in diagnosis and management (see Table I in Section 1). Work group members were asked to complete a disclosure of commercial support.

An evidence-based model was used and evidence was obtained using a search of the MEDLINE database spanning the years 1990 through 2007. Only English-language publications were reviewed.

The available evidence was evaluated using a unified system called the Strength of Recommendation Taxonomy developed by editors of the US family medicine and primary care journals (ie, American Family Physician, Family Medicine, Journal of Family Practice, and BMJ USA). This strategy was supported by a decision of the Clinical Guidelines Task Force in 2005 with some minor modifications for a consistent approach to rating the strength of the evidence of scientific studies. Evidence was graded using a 3-point scale based on the quality of methodology as follows:

I. Good-quality patient-oriented evidence.
II. Limited-quality patient-oriented evidence.
III. Other evidence including consensus guidelines, opinion, or case studies.

Clinical recommendations were developed on the best available evidence tabled in the guideline.

These are ranked as follows:
A. Recommendation based on consistent and good-quality patient-oriented evidence.
B. Recommendation based on inconsistent or limited-quality patient-oriented evidence.
C. Recommendation based on consensus, opinion, or case studies.

This guideline has been developed in accordance with the American Academy of Dermatology (AAD)/AAD Association “Administrative Regulations for Evidence-based Clinical Practice Guidelines,” which include the opportunity for review and comment by the entire AAD membership and final review and approval by the AAD Board of Directors.

INTRODUCTION

PsA is an inflammatory seronegative spondyloarthropathy associated with psoriasis. The exact proportion of patients with psoriasis who will develop PsA is an area of significant controversy with studies demonstrating a range from as low as 6% to as high as 42% of patients with psoriasis. The prevalence of PsA in the general population of the United States has been estimated to be between 0.1% to 0.25%. In a recent large clinical trial with more than 1000 patients, 84% of patients with PsA had cutaneous manifestations for an average of 12 years before the onset of PsA.

Dermatologists are strongly encouraged to actively seek signs and symptoms of PsA at each visit. If PsA is diagnosed, treatment should be initiated to alleviate signs and symptoms of PsA, inhibit structural damage, and maximize quality of life (QOL). Dermatologists uncomfortable or untrained in evaluating or treating patients with PsA should refer to rheumatologists.

PsA can develop at any time including childhood, but for most it appears between the ages of 30 and 50 years. PsA affects men and women equally. PsA is characterized by stiffness, pain, swelling, and tenderness of the joints and surrounding ligaments and tendons (dactylitis and enthesitis). The enthesitis is the anatomic location where tendon, ligament, or joint capsule fibers insert into the bone. Enthesitis may occur at any such site, although common locations include the insertion sites of the plantar fascia, the Achilles’ tendons, and ligamentous attachments to the ribs, spine, and pelvis. Dactylitis, or “sausage digit,” is a combination of enthesitis of the tendons and ligaments and synovitis involving a whole digit.

Symptoms of PsA can range from mild to very severe. The severity of the skin disease and the arthritis usually do not correlate with each other. Nail disease is commonly found in patients with PsA especially those with distal interphalangeal (DIP) joint involvement. PsA may start slowly with mild symptoms, and, on occasion, may be preceded by a joint injury.

The course of PsA is variable and unpredictable ranging from mild and nondestructive to a severe, debilitating, erosive arthropathy. Erosive and deforming arthritis occurs in 40% to 60% of patients with PsA based on data from rheumatology referral centers and may be progressive as early as within the first year of diagnosis. Studies from the general population indicate that PsA may have a milder course and that it is not associated with excess mortality. Data on the clinical course of PsA in the dermatology setting are not currently available. Flares and remissions usually characterize the course of PsA. Left untreated, patients with PsA can have persistent inflammation, progressive joint damage, severe physical limitations, disability, and increased mortality.

The spectrum of joint inflammation in PsA is great, ranging from axial to peripheral disease, synovial and adjacent soft tissue inflammation, enthesitis,
osteitis, new bone formation, and severe osteolysis, along with overlapping findings.

Characteristic radiographic features of PsA include joint erosions, joint space narrowing, bony proliferation including periarticular and shaft periostitis, osteolysis including "pencil in cup" deformity, acro-osteolysis, ankylosis, spur formation, and spondylitis. The presence of DIP erosive changes may provide both sensitive and specific radiographic findings to support the diagnosis of PsA. In patients with PsA, the hands tend to be involved much more frequently than the feet with a ratio of nearly 2:1. Dactylitis is common among patients with PsA and most often affects the feet in an asymmetric distribution. Dactylitis is associated with a greater degree of radiologic damage than occurs in digits not affected by dactylitis (Fig 1).

PATHOGENESIS

In both the skin and joints there is a prominent lymphocytic infiltrate, localized to the dermal papillae in skin and to the sublining layer stroma in the joint and inflammatory enthesis. T lymphocytes, particularly CD4+ cells, are the most common inflammatory cells in the skin and joints, with a CD4+/CD8+ ratio of 2:1 in the synovial fluid compartment, matching the ratio found in peripheral blood. CD8+ T cells are more common at the enthesis. PsA synovial tissue is characterized by a T-cell infiltrate with an increase in vascularity and a reduction in macrophages compared with the synovial tissue found in rheumatoid arthritis (RA). The synovial lymphocyte population, unlike that of the skin, does not show up-regulation of cutaneous lymphocyte-associated antigen, suggesting that different lymphocyte populations migrate to skin and synovial tissues. An important potential role for interleukin (IL)-12/23 in the pathogenesis of PsA is suggested by the finding of increased serum levels of the p40 protein (the shared subunit present on both IL-12 and IL-23) in patients with PsA when compared with healthy control subjects. Furthermore, levels of p40, epidermal growth factor, interferon-α, vascular endothelial growth factor, and macrophage inhibitory protein 1-α had the highest discriminant activity when compared with healthy control subjects, and patients with the worst PsA (>4 vs <4 involved joints) had increases in levels of p40 along with IL-2, IL-15, interferon-α, and macrophage inhibitory protein 1-α.

The observation of an increase in neutrophil infiltration in PsA is consistent with the well-described neutrophil infiltration seen in psoriasis skin and the presence of vascular endothelial growth
factor receptor positive neutrophils in PsA synovium. Angiogenesis is a prominent early event in both psoriasis and Ps. Elongated and tortuous vessels in both the skin and the joint suggest dysregulated angiogenesis resulting in immature vessels. High levels of tumor necrosis factor (TNF-\(\alpha\))-\(\alpha\), IL-8, IL-6, IL-1, IL-10, and matrix metalloproteinases are present in the joint fluid of patients with early PsA. Collagenase cleavage of cartilage collagen begins early in the disease and may result from cytokine-driven production of proteases. Treatment with anti-TNF-\(\alpha\) therapy is associated with changes in synovial macrophage subsets, reduction in T-cell and neutrophil numbers, and matrix metalloproteinase-3 expression.

Several findings suggest that osteoclast precursor cells play an important role in the pathogenesis of PsA. Osteoclast precursor cells are increased in the peripheral blood of patients with PsA and during treatment with anti-TNF agents, the frequency of osteoclast precursors decreases significantly within 2 weeks of initiating therapy. A model has been proposed whereby elevated serum levels of TNF lead to an increase in the frequency of circulating osteoclast precursors. Osteoclast precursors then migrate to the joint where they encounter increased expression of receptor activator of nuclear factor kappa B ligand, which favors the differentiation and activation of osteoclasts. Once formed, osteoclasts are exposed to a variety of activating molecules in the PsA joint, including TNF and IL-1 that trigger osteoclast activation that may, if unchecked, eventuate in osteolysis.

**PROGNOSIS**

The prognosis of PsA may range widely from a mild monoarticular form with a good prognosis to an erosive and destructive polyarticular form with a poor prognosis, comparable in severity with that found in patients with RA. Although it is generally not possible to accurately predict which patients may progress to disabling PsA, one study of 71 patients suggests that a polyarticular onset (\(\geq 5\) swollen joints) of PsA may predict the appearance of erosive and deforming disease over time, thus necessitating early intervention with effective therapy.

Much like RA, PsA can lead to chronic joint damage, increased disability, and increased mortality. Social and financial implications are also important, both in terms of personal loss and the impact of direct (eg, medical care) and indirect (eg, inability to work) costs to the society and patient.

**CLASSIFICATION**

The classification of PsA is an area of ongoing international discussion. Although the 5 subgroups originally proposed by Moll and Wright\(^9\) in 1973 are frequently used (Table I), considerable overlap between these groups is now recognized. The recently developed CASPAR (classification criteria for PsA) criteria consist of established inflammatory articular disease*, with at least 3 points from the following features:

A. Current psoriasis (assigned a score of 2; all other features are assigned a score of 1)
B. A personal history of psoriasis (unless current psoriasis is present)
C. A family history of psoriasis (unless current psoriasis is present or there is a personal history of psoriasis)
D. Current dactylitis or history of dactylitis recorded by a rheumatologist
E. Juxta-articular new bone formation
F. Rheumatoid factor negativity
G. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis

*Prolonged morning or immobility-induced stiffness, and tender and swollen joints suggest an inflammatory joint disease.

### Table I. Moll and Wright\(^9\) criteria for psoriatic arthritis

- Polyarticular, symmetric arthritis (rheumatoid arthritis-like)
- Oligoarticular (<5 joints), asymmetric arthritis
- Distal interphalangeal joint predominant
- Spondylitis predominant
- Arthritis mutilans

To meet the Moll and Wright\(^9\) 1973 classification criteria for psoriatic arthritis, a patient with psoriasis and inflammatory arthritis who is seronegative for rheumatoid arthritis must present with 1 of the above 5 clinical subtypes. Moll and Wright\(^9\) specificity is 98% and sensitivity is 91%.

### Table II. CASPAR criteria for the diagnosis of psoriatic arthritis (modified\(^{10}\))

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established inflammatory arthritis</td>
<td>1</td>
</tr>
<tr>
<td>Prolonged morning or immobility-induced stiffness</td>
<td>1</td>
</tr>
<tr>
<td>Tender and swollen joints</td>
<td>1</td>
</tr>
</tbody>
</table>

The CASPAR (classification criteria for psoriatic arthritis) criteria consist of established inflammatory articular disease* with at least 3 points from the following features:

A. Current psoriasis (assigned a score of 2; all other features are assigned a score of 1)
B. A personal history of psoriasis (unless current psoriasis is present)
C. A family history of psoriasis (unless current psoriasis is present or there is a personal history of psoriasis)
D. Current dactylitis or history of dactylitis recorded by a rheumatologist
E. Juxta-articular new bone formation
F. Rheumatoid factor negativity
G. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis

*Prolonged morning or immobility-induced stiffness, and tender and swollen joints suggest an inflammatory joint disease.

The diagnosis of PsA is based on clinical judgment. Specific patterns of joint inflammation together with the absence of rheumatoid factor and the presence of skin and nail lesions of psoriasis aid clinicians in making the diagnosis of PsA. Although there are no specific serologic tests to confirm the diagnosis of PsA, radiographs can be helpful for diagnosis, to demonstrate the extent and location of...
joint damage, and to distinguish PsA from either RA or inflammatory osteoarthritis. Radiograph changes may occur early in the course of PsA.

There are two major patterns of arthritis in PsA: peripheral joint disease, which can be polyarticular or pauciarticular, and skeletal or axial disease. Approximately 95% of patients with PsA have involvement of the peripheral joints, predominantly the polyarticular form, whereas a minority have the oligoarticular form. About 5% of patients have exclusively axial involvement, whereas 20% to 50% of patients have involvement of both the spine and the peripheral joints, with peripheral joint involvement being the predominant pattern. Asymptomatic involvement of the spine and sacroiliac joints may occur in patients with PsA. Radiographs, and in some cases, magnetic resonance imaging and/or computed tomography imaging, can be helpful in detecting asymptomatic disease. The subclassification of PsA into mild, moderate, and severe is defined in Table III.

**COMPARISON OF PSA WITH RA**

As shown in Table IV, the peripheral polyarticular pattern of PsA may share several features with RA. Clinical features are important to differentiate seronegative (rheumatoid factor—negative) RA with coincidental psoriasis from patients with peripheral PsA. The presence of psoriatic plaques or nail psoriasis helps to establish a diagnosis of PsA. Patients who display other characteristic signs of RA (ie, rheumatoid nodules, extra-articular involvement, and high titers of rheumatoid factor) should not be given the diagnosis of PsA. Involved joints in PsA are usually less tender and swollen and less symmetric in distribution than in RA. However, 20% of patients with PsA, especially female patients, have a symmetric polyarticular inflammatory arthritis resembling RA being differentiated by the presence of cutaneous or nail findings. Dactylitis, enthesitis, and DIP joint involvement common in PsA are uncommon in RA.

**COMPARISON OF PSA WITH OSTEOARTHRITIS**

As shown in Table IV, another important differential diagnosis for dermatologists to consider in patients with psoriasis who have joint symptoms is osteoarthritis. In the hands, there may be DIP involvement in both PsA and osteoarthritis but the classic DIP-related Heberden’s nodes in osteoarthritis are bone spurs whereas in PsA the DIP involvement is joint inflammation. Although morning stiffness and stiffness after prolonged inactivity such as air or automobile travel are common in PsA, stiffness tends to occur with joint activity in patients with osteoarthritis. Although PsA occurs equally in men and women, osteoarthritis of the hands and feet is more frequent in women. Enthesitis, dactylitis, and sacroiliitis are generally not present in patients with osteoarthritis.

**COMPARISON OF AXIAL PSA WITH ANKYLOSING SPONDYLITIS**

As shown in Table IV, patients with PsA who have axial disease (psoriatic spondylitis) may have similar clinical findings to patients with ankylosing spondylitis (AS). However, patients with PsA are often less symptomatic, have asymmetric disease, and tend to have less severe disease. In addition, the psoriatic plaques or nail changes present in patients with psoriatic spondylitis are absent in patients with AS. Although axial involvement in most patients with PsA is a secondary feature of a predominantly peripheral arthritis, axial PsA may present either as sacroiliitis, often asymmetric and asymptomatic, or spondylitis affecting any level of the spine in a “skip” fashion. When compared with patients with AS, patients with PsA seldom have impaired mobility or progress to ankylosis (total loss of joint space).

**IMPORTANT CLINICAL POINTS TO HELP PRACTITIONERS IN THE DIAGNOSIS OF PSA**

It is important for dermatologists to draw on both history and physical findings in making a diagnosis of an inflammatory arthritis like PsA. Helpful clues

---

**Table III. Definition of mild, moderate, and severe psoriatic arthritis**

<table>
<thead>
<tr>
<th>Severity</th>
<th>Response to therapy</th>
<th>Impact on QOL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>NSAIDs</td>
<td>Minimal Impacts daily tasks of living and physical/mental functions; lack of response to NSAIDs</td>
</tr>
<tr>
<td>Moderate</td>
<td>Requires DMARDs or TNF blockers</td>
<td>Impacts daily tasks of living and physical/mental functions; lack of response to NSAIDs</td>
</tr>
<tr>
<td>Severe</td>
<td>Requires DMARDs plus TNF blockers or other biologic therapies</td>
<td>Cannot perform major daily tasks of living without pain or dysfunction; large impact on physical/mental functions; lack of response to either DMARDs or TNF blockers as monotherapy</td>
</tr>
</tbody>
</table>

include joint stiffness that lasts more than 30 to 45 minutes in the morning or after long periods of inactivity such as sleep, automobile trips, or air travel. The presence of an inflamed and swollen digit (dactylitis) or of enthesitis (inflammation at sites of tendon insertion such as the Achilles' tendon or the plantar fascia) makes evaluation of hands and feet, plus large joints, an important consideration in making a diagnosis of PsA. In clinical practice, the physician generally uses subjective qualitative assessment of the severity of a patient's PsA. This assessment combines an objective assessment of the degree of joint involvement, including level of pain, joint tenderness and/or swelling, degree of joint destruction as assessed by radiograph findings, and its effect on the ability of the patient to adequately perform their routine tasks of daily living, along with a subjective assessment of the physical, financial, and emotional impact of the disease on the patient’s QOL.

**Table IV.** Comparison of psoriatic arthritis with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis

<table>
<thead>
<tr>
<th></th>
<th>PsA</th>
<th>RA</th>
<th>OA</th>
<th>AS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peripheral disease</strong></td>
<td>Asymmetric</td>
<td>Symmetric</td>
<td>Asymmetric</td>
<td>No</td>
</tr>
<tr>
<td><strong>Sacroiliitis</strong></td>
<td>Asymmetric</td>
<td>No</td>
<td>No</td>
<td>Symmetric</td>
</tr>
<tr>
<td><strong>Stiffness</strong></td>
<td>In morning and/or with immobility</td>
<td>In morning and/or with immobility</td>
<td>With activity</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Female:Male ratio</strong></td>
<td>1:1</td>
<td>3:1</td>
<td>Hand/foot more common in female patients</td>
<td>1:3</td>
</tr>
<tr>
<td><strong>Enthesitis</strong></td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>High titer rheumatoid factor</strong></td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>HLA association</strong></td>
<td>CW6, B27</td>
<td>DR4</td>
<td>No</td>
<td>B27</td>
</tr>
<tr>
<td><strong>Nail lesions</strong></td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Psoriasis</strong></td>
<td>Yes</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

AS, Ankylosing spondylitis; OA, osteoarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.

**Table V.** American College of Rheumatology scoring

1. ≥ 20% reduction in the tender joint count
2. ≥ 20% reduction in the swollen joint count
3. ≥ 20% reduction in 3 of 5 additional measures including:
   a. patient assessment of pain
   b. patient global assessment of disease activity
   c. physician global assessment of disease activity
   d. disability index of the Health Assessment Questionnaire
   e. acute phase reactants, ie, erythrocyte sedimentation rate and C-reactive protein

American College of Rheumatology (ACR)50 and ACR70 analysis include the same criteria as ACR20, with the use of a higher percentage improvement (50% and 70%).

include joint stiffness that lasts more than 30 to 45 minutes in the morning or after long periods of inactivity such as sleep, automobile trips, or air travel. The presence of an inflamed and swollen digit (dactylitis) or of enthesitis (inflammation at sites of tendon insertion such as the Achilles’ tendon or the plantar fascia) makes evaluation of hands and feet, plus large joints, an important consideration in making a diagnosis of PsA. In clinical practice, the physician generally uses subjective qualitative assessment of the severity of a patient’s PsA. This assessment combines an objective assessment of the degree of joint involvement, including level of pain, joint tenderness and/or swelling, degree of joint destruction as assessed by radiograph findings, and its effect on the ability of the patient to adequately perform their routine tasks of daily living, along with a subjective assessment of the physical, financial, and emotional impact of the disease on the patient’s QOL.

**ASSESSMENT TOOLS USED TO EVALUATE PSA TREATMENT**

**AMERICAN COLLEGE OF RHEUMATOLOGY SCORING**

As shown in Table V, The American College of Rheumatology (ACR) scoring system (ACR20/50/70) was originally developed for the clinical evaluation of therapies used to treat RA. The ACR20 scoring criteria are described in Table V. ACR20 response criteria have been used as the primary end point for the majority of clinical trials in PsA, with ACR50/70 response rates as secondary end points. As the pattern of peripheral joint involvement in PsA is different from that of RA, it is important that the DIP joints of the hands and both the proximal interphalangeal and DIP joints of the feet are counted (ie, a total of 68/66 joints) and assessed for tenderness/swelling. A disadvantage of the ACR measurement technique is the time delay required to obtain the results of the C-reactive protein or erythrocyte sedimentation rate studies.16

**DISEASE ACTIVITY SCORE**

The Disease Activity Score (DAS), used primarily in Europe, was originally developed as a 44- or 28-joint count used in the assessment of RA. In PsA clinical trials a 78 tender and 76 swollen joint count is frequently used to accommodate the commonly involved DIP and carpal-metacarpal joints.17 The DAS scoring system uses a weighted mathematic formula, derived from clinical trials in RA. Although the ACR rating system only represents change, the DAS system represents current state of disease activity and change. A disadvantage of the DAS rating system is that it requires use of a calculator (square roots are in the formula). Although the ACR20 and DAS scores have been the most widely used...
assessment tools in PsA trials, investigation into outcomes measures that do not require blood testing or use of a calculator is ongoing.

PSA RESPONSE CRITERIA

The PsA Response Criteria (PsARC) was specifically developed for PsA and originally used in a large study of sulfasalazine in PsA. The PsARC is defined as improvement in at least two of the following 4 criteria: (1) 20% or more improvement in physician global assessment of disease activity; (2) 20% or more improvement in patient global assessment of disease activity; (3) 30% or more improvement in tender joint count; and (4) 30% or more improvement in swollen joint count. A mandatory component when using the PsARC is improvement in tender or swollen joint count. Furthermore, no worsening in any PsARC component should be observed. Although the PsARC discriminates well between effective treatment and placebo, it does have significant limitations. These include the PsARC's focus on the peripheral manifestations of PsA, along with its diminished capacity to capture features that are distinctive to PsA such as dactylitis and enthesitis.

RADIOLOGIC FEATURES

Structural damage from PsA can be assessed on conventional radiographs and is an important outcome measure in judging the efficacy of treatment. The most frequently involved joints are those in the hands and wrists, followed by the feet, ankles, knees, and shoulders with DIP involvement, along with an asymmetric pattern being characteristic features of PsA.

The radiographic features of PsA can be grouped into destructive and proliferative changes. Erosions are a typical destructive feature, frequently starting at the margins of joints and then progressing toward the center. Erosions with accompanying increased bone production are typical in PsA and may become extensive enough to give the appearance of a widened joint, rather than a narrowed joint space. Widespread erosive changes may lead to the characteristic “pencil in cup” phenomenon produced by a blunt osseous surface on the proximal bone of a joint protruding into an expanded surface of the distal bone of the joint. Marked osteolysis may be observed in severely destroyed joints, such that the whole phalanx may be destroyed. Ankylosis of joints may also be observed.13

SCORING METHODS

Several scoring methods for the assessment of structural damage in peripheral joints in PsA have been proposed, adapted for use from existing scoring systems for RA. Scoring methods developed for use in AS have been successfully applied to assess spine and sacroiliac joint abnormalities in PsA.18

PSA SCORING BASED ON THE SHARP METHOD FOR RA

In developing a scoring method for PsA, erosions, joint space narrowing, and radiographic changes should be scored (Table VI).

SHARP-VAN DER HEIJDE MODIFIED SCORING METHOD FOR PSA

This method, adopted from RA, is a detailed scoring method evaluating erosions, joint space narrowing, subluxation, ankylosis, gross osteolysis, and “pencil in cup” phenomena. In addition to the joints evaluated for RA, the DIPs of the hands are also assessed in PsA.

QUALITY OF LIFE

QOL may be assessed either using specific scales such as the PsAQOL index or more generic instruments such as the short form-36, the Health

Table VI. Sharp scoring

| A. Erosions |  
| --- | --- |
| Hands |  
| Second-fifth DIP joints |  
| All 5 metacarpophalangeal joints |  
| The interphalangeal joint of the thumb |  
| Wrist bones including first metacarpal base, the multangulars, the navicular, the lunate, the triquetrum and pisiform, the radius, and the ulna |  
| Feet |  
| All 5 metatarsal joints |  
| Interphalangeal joint of the great toe |  
| B. Joint space narrowing |  
| Hands |  
| Second-fifth DIP joints |  
| All 5 metacarpophalangeal joints |  
| Wrist bones including fourth, fifth, and sixth carpometacarpal joints, the multangular-navicular, capitate-navicular, capitate-lunate, and radiocarpal joints |  
| Feet |  
| All 5 metatarsal joints |  
| C. Radiographic changes |  
| Shaft periostitis |  
| Juxta-articular periostitis |  
| Periostitis in the wrist |  
| Tuft resorption |  

DIP, Distal interphalangeal.
Assessment Questionnaire (HAQ), and the Functional Assessment of Chronic Illness Therapy. These QOL tools have been tested in PsA and found to be reliable, valid, and responsive to change. The effect of psoriasis and PsA on health-related QOL should be assessed independently. 19

TREATMENT

Mild PsA

Appropriate treatment of PsA may include physical therapy, patient education, and medication. Because only half of patients with PsA have progressive disease, mild PsA is quite common and often successfully treated with nonsteroidal anti-inflammatory drugs (NSAIDs). 20 When only a few joints are involved in patients with PsA, rheumatologists may perform local intra-articular injections of corticosteroids. Although both NSAIDs and intra-articular injections of corticosteroids can lead to good symptomatic relief for patients with mild PsA, neither treatment is capable of inhibiting the development of structural joint damage.

USE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TO TREAT MODERATE TO SEVERE PSA

Patients with moderate to severe PsA that is more extensive or aggressive in nature require more potent therapy than NSAIDs or intra-articular corticosteroid injections, ie, disease-modifying antirheumatic drugs (DMARDs). Unfortunately, clinical trials evaluating the efficacy of DMARDs in PsA are few, include small patient numbers, and show only moderate efficacy with high placebo responses. 20

Methotrexate

The data supporting the efficacy of methotrexate in PsA, which include two randomized, placebo-controlled trials, are inadequately powered to assess clinical benefit. The first study, performed in 1964, evaluated 21 patients with PsA who were treated with 3 intramuscular injections of methotrexate at 10-day intervals. This treatment resulted in a decrease in joint tenderness, swelling, and the erythrocyte sedimentation rate. 21 In the second study, 37 patients were treated with between 7.5 and 15 mg/wk of methotrexate or placebo. After 12 weeks, the methotrexate group showed superior physician assessment of arthritis activity compared with placebo group. 22 Despite the paucity of evidence demonstrating its clinical benefit, methotrexate is frequently used as the primary DMARD in PsA, because of its efficacy in treating both skin and joint involvement in patients with psoriatic disease and its low cost.

Other DMARDs

Sulfasalazine showed modest benefit in a study of 221 patients with PsA. After 36 weeks of treatment, 58% of patients treated with sulfasalazine as compared with 45% of patients treated with placebo achieved the PsARC. 23 Leflunomide, a selective pyrimidine synthesis inhibitor that targets activated T lymphocytes, was studied in a randomized, double-blind, placebo-controlled study of 188 patients with active PsA. After 6 months, 59% of patients treated with leflunomide achieved the PsARC, compared with 30% of patients treated with placebo. 24 Other DMARDs including antimalarials, cyclosporine, and gold are less frequently used because evidence for their efficacy is even less convincing than for methotrexate, sulfasalazine, and leflunomide. 20

For patients with moderate to severe PsA that is more extensive or aggressive in nature or that impacts QOL significantly, treatment with methotrexate, TNF blockers, or both is the standard of care. Although the efficacy of DMARDs appears to be less than for the TNF inhibitors in the limited studies available, prospective, randomized, adequately powered, comparative, head-to-head trials are lacking to support or refute this impression.

Numerous medications intended to treat PsA may also have an effect on psoriasis. For example, most dermatologists avoid systemic corticosteroids in the treatment of patients with psoriasis because of the potential risk of pustular and erythrodermic flares when systemic corticosteroids are discontinued. However, rheumatologists often use systemic corticosteroids in the short- and long-term treatment of PsA, in significantly smaller dosages (5-10 mg/d) than dermatologists traditionally use in chronic dermatoses. Between 10% and 20% of patients entered into the pivotal clinical trials of adalimumab, etanercept, and infliximab for PsA were treated with concurrent systemic corticosteroids with minimal observed adverse outcomes. 25-27 Worsening of skin disease with initiation of NSAID therapy is occasionally observed with both nonspecific and cyclo-oxygenase-2-specific NSAIDs with shunting of arachidonic acid metabolites down the leukotriene pathway postulated as a potential mechanism. By contrast, treatments such as methotrexate and TNF-α antagonists are useful for both the skin and joint manifestations of PsA.

In the last 10 years, there has been growing interest in the pivotal role that TNF, a proinflammatory cytokine, plays in inflammation of skin and synovium and this molecule has become a logical target for treatment in PsA with multiple clinical trials demonstrating that TNF-α blockade is effective in the
treatment of PsA. Three TNF-α antagonists, adalimumab, etanercept, and infliximab, are currently Food and Drug Administration (FDA)-approved for the treatment of PsA.

Although TNF-α antagonists are expensive compared with DMARDs, there are potential long-term cost savings and long-term benefits. These include reduced need for joint replacement surgery; reduced demands on medical, nursing, and therapy services; reduced needs for concomitant medicines; reduced demands on social services and careers; improved QOL; improved prospect of remaining in the work force; and increased life expectancy.28

**GENERAL RECOMMENDATIONS FOR PSA**

Dermatologists are strongly encouraged to consider the possible concurrent diagnosis of PsA in patients presenting with psoriasis. Although a history and screening examination for PsA should be performed at every visit, there are as yet no broadly validated, user-friendly, sensitive, and specific screening tools available specifically for dermatologists to use. The development of one such instrument is in progress. The PsA Screening and Evaluation tool was developed to screen patients with psoriasis for signs and symptoms of inflammatory arthritis.29 In pilot testing, 69 patients with known psoriasis and PsA before the initiation of systemic therapy were screened using a 15-item questionnaire. Using this self-administered patient tool, a PsA Screening and Evaluation total score of 47 or higher distinguished patients with PsA from patients without PsA (largely patients with osteoarthritis) with 82% sensitivity and 73% specificity. Larger studies of the PsA Screening and Evaluation tool will be necessary to verify its value as a screening tool for PsA. Dermatologists uncomfortable evaluating or treating patients with PsA should refer patients who they suspect may have PsA to rheumatologists.

Upon diagnosis of PsA, patients should be treated and/or referred to a rheumatologist to alleviate signs and symptoms, inhibit structural damage, and improve QOL parameters.

Methotrexate, TNF blockade, or the combination of these therapies is considered first-line treatment for patients with moderate to severely active PsA. Although there are no prognostic indicators to identify these patients early, approximately 50% of patients with PsA may develop structural damage.

Not all patients with PsA require treatment with methotrexate or TNF blockade. Patients with mild PsA can be successfully treated with NSAIDs or intra-articular injections of corticosteroids.

**Table VII. The strength of recommendations for treatment of psoriatic arthritis using tumor necrosis factor inhibitors**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength of recommendation</th>
<th>Level of evidence</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>A</td>
<td>I</td>
<td>26, 31</td>
</tr>
<tr>
<td>Etanercept</td>
<td>A</td>
<td>I</td>
<td>17, 27, 32</td>
</tr>
<tr>
<td>Infliximab</td>
<td>A</td>
<td>I</td>
<td>25, 33</td>
</tr>
</tbody>
</table>

Because the clinical trial ACR20 efficacy data at the primary end point with all 3 FDA-approved TNF blockers for the treatment of PsA are roughly equivalent, the choice of which TNF agent to use is an individual one with the degree and severity of cutaneous involvement an important consideration. Common safety concerns need to be considered when treating patients who have PsA with TNF inhibitors.

**GENERAL RECOMMENDATIONS FOR ALL PATIENTS WITH PSA WHO WILL BE TREATED WITH BIOLOGICS**

An extensive discussion regarding general recommendations for the treatment of patients with psoriasis has been presented in Section 1 of these guidelines devoted to the use of biologics for the treatment of psoriasis. We will not recapitulate this information here, which includes suggestions for laboratory evaluation and issues related to vaccination. The reader is directed to this discussion in Section 1.

**TNF INHIBITORS FOR THE TREATMENT OF PSA**

The potential importance of TNF-α in the pathophysiology of PsA is underscored by the observation that there are elevated levels of TNF-α in the synovium, joint fluid, and skin of patients with PsA.30

**EFFICACY OF THE TNF INHIBITORS IN PSA**

The strength of recommendations for the treatment of PsA using biologics that target TNF are shown in Table VII. When TNF inhibitors are used in the treatment of patients with PsA, they are often combined with DMARDs, particularly methotrexate. This combination approach is considered by many to be the standard of care for the treatment of PsA. However, prospective, randomized, adequately powered clinical trials, comparing the combination of methotrexate with TNF blockade with either agent alone (as performed in RA), have not been performed in PsA. The results of the use of the 3 TNF
Adalimumab efficacy

In a phase III study of 313 patients with PsA, adalimumab showed significant benefit for the treatment of PsA.26 Adalimumab was administered subcutaneously at 40 mg every other week or weekly. In the double-blinded portion of the study at 24 weeks, 57% of patients receiving adalimumab (40 mg every other week) achieved ACR20 response compared with 15% of patients receiving placebo ($P < .001$). At week 24, the ACR50 and ACR70 response rates were 39% and 23% for patients treated with adalimumab compared with 6% and 1% for patients receiving placebo, respectively ($P < .001$). The response rate did not differ between patients taking adalimumab in combination with methotrexate (50% of patients) and those taking adalimumab alone, although the numbers of patients in each cohort were too small to have adequate statistical power. Mean improvement in enthesitis and dactylitis was greater for patients receiving adalimumab than placebo, but this result did not achieve statistical significance. Using a modified Sharp score, radiographic progression of hand and foot joint disease was significantly inhibited by adalimumab. Mean change in the modified Sharp score was −0.2 for patients receiving adalimumab and 1.0 for patients receiving placebo ($P < .001$). Mean change in the HAQ was −0.4 for patients taking adalimumab and −0.1 for patients taking placebo ($P < .001$).

Patients who completed the 24-week double-blind portion of the study were eligible to enter an open-label phase where they received 40 mg of adalimumab every other week for another 24 weeks. The ACR20, ACR50, and ACR70 response rates for patients who had been on adalimumab for 48 weeks and 0.9 and 1.0, respectively, for patients who received placebo for 24 weeks followed by adalimumab for 24 weeks. There was convincing evidence for both clinical and radiographic efficacy of adalimumab regardless of whether patients were or were not taking methotrexate at baseline. Recommendations for adalimumab are listed in Table VIII.

Etanercept efficacy

In a phase III study of 205 patients with PsA, etanercept showed significant improvement in signs and symptoms of PsA.27 Etanercept was administered subcutaneously at 25 mg given twice weekly. Significant improvement in all outcome measures was achieved with etanercept treatment, including the number of tender joints, number of swollen joints, morning stiffness, C-reactive protein levels, and both physician and patient global ratings. In this study, 59% of patients taking etanercept as compared with 19% of patients taking placebo achieved an ACR20 response at 12 weeks ($P < .0001$).27 Response to etanercept was independent of concurrent methotrexate use (46% of patients in the study were using concurrent methotrexate at a mean dosage of 16 mg/wk), although the numbers of patients in each cohort were too small to have adequate statistical power, similar to observations made in the adalimumab PsA trial. Radiographic disease progression was inhibited in the etanercept group at 12 months; the mean annualized rate of change in the modified total Sharp score was −0.03 U, compared with +1.00 U in the placebo group ($P = .0001$).27 Of the 169 patients who participated in an open-label follow-up use of etanercept between 1 and 2 years, the modified total Sharp score in the 141 patients evaluated showed a change of −0.38 and −0.22 U in the original etanercept and placebo groups, respectively, indicating continued inhibition of joint structural damage.27 Recommendations for etanercept are listed in Table IX.

### Table VIII. Recommendations for adalimumab

- **Indications:** moderate/severe psoriatic arthritis; moderate/severe psoriasis; adult and juvenile rheumatoid arthritis (as young as 4 y); ankylosing spondylitis; and adult Crohn’s disease
- **Dosing:** 40 mg every other wk subcutaneously
- **Response:** ACR20 at wk 12 is 58%
- **Toxicities:** see Table VII in Psoriasis Guidelines in Section 1

**ACR,** American College of Rheumatology.

*Indicators for the treatment of PsA will be reviewed in alphabetic order.

### Table IX. Recommendations for etanercept

- **Indications:** moderate/severe psoriatic arthritis; moderate/severe psoriasis; adult and juvenile rheumatoid arthritis (as young as 4 y); and ankylosing spondylitis
- **Dosing:** 25 mg twice wk or 50 mg once wk given subcutaneously
- **Response:** ACR20 at wk 12 is 59%
- **Toxicities:** see Table VIII in Psoriasis Guidelines in Section 1
- **Baseline and ongoing monitoring:** see Table VIII in Psoriasis Guidelines in Section 1

**ACR**, American College of Rheumatology.
Infliximab efficacy

In a phase III study of 200 patients with PsA, infliximab showed significant benefit for the treatment of PsA.\textsuperscript{25} Infliximab was dosed at 5 mg/kg and administered intravenously at weeks 0, 2, and 6, followed by infusions every 8 weeks. Baseline demographic and disease activity characteristics were similar to those of the etanercept PsA phase III trial. At week 14, 58\% of patients taking infliximab and 11\% of patients taking placebo achieved an ACR20 response (\(P < .001\)). Response to infliximab was independent of concurrent methotrexate use (46\% of patients in the study were using concurrent methotrexate at a mean dosage of 16 mg/wk) although the numbers of patients in each cohort were too small to have adequate statistical power, similar to observations made in the adalimumab and etanercept PsA trials. At 6 months, a higher number of patients treated with infliximab achieved ACR20/50/70 responses when compared with those receiving placebo treatment (54\%, 41\%, 27\% vs 16\%, 4\%, 2\%, respectively). The presence of dactylitis decreased in the infliximab group (41\%-18\%) compared with the placebo group (40\%-30\%) (\(P = .025\)). Likewise, the presence of enthesitis, assessed by palpation of the Achilles’ tendon and plantar fascia insertions, decreased in the infliximab group (42\%-22\%) compared with the placebo group (35\%-34\%) (\(P = .016\)). Using the Sharp-van der Heijde scoring method (for the hands and feet), modified for PsA, patients treated with infliximab showed inhibition of radiographic disease progression at 24 weeks; HAQ scores improved for 59\% of patients taking infliximab, compared with 19\% of patients taking placebo, whereas both the physical and mental components of short form-36 scores improved for patients receiving infliximab. The improvement in PsA by infliximab was sustained at 1 year.\textsuperscript{35} Recommendations for infliximab are shown in Table X.

GENERAL SAFETY RECOMMENDATIONS FOR PATIENTS WITH PSA WHO WILL BE TREATED WITH TNF INHIBITORS

The TNF inhibitors have been available for more than 10 years, primarily for the treatment of inflammatory bowel disease and RA, with more than 1.5 million patients to date having been treated for all indications worldwide. In recent years, the indications for the use of TNF inhibitors have expanded to include PsA and psoriasis. An extensive discussion about the general safety issues of all the TNF inhibitors, derived in large part from observations made from their use in RA and inflammatory bowel disease, has been presented in part one of these guidelines devoted to the use of biologics for the treatment of psoriasis. We will, therefore, not recapitulate this information here, which also includes safety issues specific for individual TNF inhibitors described in Section 1. It is important to recognize that patients with PsA, as compared with patients with skin involvement only, have a higher likelihood of being treated with the combination of a TNF inhibitor and a DMARD (usually methotrexate). Thus, the general TNF inhibitor safety data detailed at length in the first portion of these guidelines will, of necessity, need to be carefully reviewed to take the combination therapy into consideration.

ALEFACEPT IN PSA

Alefacept, approved for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic agents or phototherapy, is not FDA approved for PsA, but was studied as a therapy for PsA in a phase II trial in combination with methotrexate, and compared with methotrexate alone. Standard dose alefacept (15 mg) or placebo was administered intramuscularly once weekly for 12 weeks in combination with methotrexate, followed by 12 weeks of observation during which only methotrexate treatment was continued with the primary efficacy end point being the proportion of patients achieving an ACR20 response at week 24.\textsuperscript{34}

In all, 185 patients were randomly assigned to receive alefacept plus methotrexate (\(n = 123\)) or placebo plus methotrexate (\(n = 62\)) (mean dosage of methotrexate of 14 mg/wk). At week 24, 54\% of patients in the alefacept plus methotrexate group achieved an ACR20 response, compared with 23\% of patients in the placebo plus methotrexate group (\(P < .001\)).\textsuperscript{34} The safety profile of patients treated with alefacept plus methotrexate in this trial showed no significant liver abnormalities or other toxicities. Alefacept predictably reduced CD4 T-cell counts; however, no patient discontinued alefacept because of low CD4 T-cell counts, and no association was

Table X. Recommendations for infliximab

<table>
<thead>
<tr>
<th>Recommendations for infliximab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications:</strong> moderate/severe psoriatic arthritis; severe psoriasis; adult rheumatoid arthritis; ankylosing spondylitis; and Crohn’s disease (pediatric and adult)</td>
</tr>
<tr>
<td><strong>Dosing:</strong> 5 mg/kg given intravenously at wk 0, 2, and 6, and then every 6-8 wk; dose and interval of infusions may be adjusted as needed</td>
</tr>
<tr>
<td><strong>Response:</strong> ACR20 at wk 14 is 58%</td>
</tr>
<tr>
<td><strong>Toxicities:</strong> see Table IX in Psoriasis Guidelines in Section 1</td>
</tr>
<tr>
<td><strong>Baseline and ongoing monitoring:</strong> see Table IX in Psoriasis Guidelines in Section 1</td>
</tr>
</tbody>
</table>

ACR, American College of Rheumatology.
apparent between CD4 T-cell counts and the incidence of infection. Reductions in CD4 T-cell counts in patients treated with alefacept plus methotrexate were consistent with those reported in the clinical trials of alefacept monotherapy in patients with psoriasis. Results of this phase II trial suggest that alefacept in combination with methotrexate may be an effective and well-tolerated therapeutic option for some patients with PsA. Further studies are warranted to confirm these findings.

CONCLUSIONS

PsA is an inflammatory arthropathy associated with psoriasis. Left untreated, a proportion of patients with PsA may develop persistent inflammation with progressive joint damage that can lead to severe physical limitations and disability. Several viable treatment options are available to treat PsA. These include NSAIDs and/or intra-articular injections of corticosteroids for patients with milder, localized PsA, and DMARDs including methotrexate and/or biologics (the TNF inhibitors) for patients with more severe PsA. Because PsA can be a very severe disease with significant functional impairment, early diagnosis is critical. Early diagnosis of PsA affords the caregiver the opportunity to improve QOL, improve function, and slow disease progression. Because the large majority of patients (84%) with PsA have psoriasis for approximately 12 years before developing joint symptoms, dermatologists are in an excellent position to make this diagnosis and treat PsA appropriately. Therefore, we strongly encourage dermatologists to actively seek signs and symptoms of PsA at every patient visit. If PsA is diagnosed, treatment should be initiated to alleviate signs and symptoms of PsA, inhibit structural damage, and maximize QOL. Dermatologists uncomfortable or untrained in evaluating or treating patients with PsA should refer to rheumatologists.

We thank Bruce Strober MD, PhD, Alexa Kimball, MD, MPH, and the Clinical Research Committee: Karl A. Beutner, MD, PhD, Chair, Michael E. Bigby, MD, Craig A. Elmets, MD, Dirk Michael Elston, MD, Joel M. Gelfand, MD, MSCE, Jacqueline M. Junkins-Hopkins, MD, Pearson G. Lang Jr, MD, Gary D. Monheith, MD, Abrar A. Qureshi, MD, MPH, Ben M. Treen, MD, Stephen B. Webster, MD, Lorraine C. Young, MD, Carol K. SIEck, RN, MSN, and Terri Zylo for reviewing the manuscripts and providing excellent suggestions.

Conflicts of interest: Alice Gottlieb, MD, PhD: Dr Gottlieb served as a speaker for Amgen Inc and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen, Inc, Centocor, Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf, Inc, Warner Chilcott, Abbott Labs, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipors Ltd, Medacorpor, DermpisPor, Can-Fite, and Incyte; and has received research/educational grants from Centocor, Amgen, Wyeth, Immune Control, Celgene, Pharmcare, and Incyte. All income has been paid to her employer directly.

Neil J. Korman, MD, PhD: Dr Korman has served on the Advisory Board and was investigator and speaker for Abbott Labs, Genentech, and Astellas, receiving grants and honoraria; served on the Advisory Board and was investigator for Centocor, receiving grants and residency/fellowship program funding; and was investigator and speaker for Amgen, receiving grants and honoraria.

Kenneth B. Gordon, MD: Dr Gordon served on the Advisory Board and was consultant, investigator, and speaker for Abbott Labs, Amgen, and was a consultant and investigator for Centocor, receiving grants and honoraria; and was investigator for Genentech, receiving grants. Steven R. Feldman, MD, PhD: Dr Feldman served on the Advisory Board and was investigator and speaker for Galderma, Stiefel, Warner Chilcott, Abbott Labs, and Astellas, receiving grants and honoraria; served on the Advisory Board for Photomedex, receiving stock options; served on the advisory board and was speaker for National Psoriasis Foundation, receiving honoraria; and was an investigator and speaker for Amgen, Centocor, and Genentech, receiving grants and honoraria.

Mark Lebwohl, MD: Dr Lebwohl served on the Advisory Board and was consultant, investigator, and speaker for Abbott Labs, Amgen, Centocor, Galderma, Genentech, and Warner Chilcott, receiving honoraria and grants; served on the Advisory Board and was consultant, investigator, and speaker for Stiefel, receiving honoraria; was consultant and investigator for Astellas, receiving grants and honoraria; was consultant investigator for Biogen, UCB, and Isetochnika, receiving honoraria; was on the Advisory Board and was consultant and investigator for Novartis, receiving grants and honoraria; and had an “other” relationship with PharmaDerm, receiving grants and honoraria.

John Y. M. Koo, MD: Dr Koo served on the Advisory Board, was speaker, consultant, and investigator for Amgen, Abbott Labs, Astellas, Warner Chilcott, and Galderma, receiving grants and honoraria; was investigator for Genentech, receiving grants; and was on the Advisory Board and was a consultant and investigator for Teikokio receiving no compensation.

Abby S. Van Voorhees, MD: Dr Van Voorhees served on the Advisory Board, was an investigator and speaker for Amgen, Bristol Myers Squibb, and Warner Chilcott, receiving grants and honoraria; and was on the Advisory Board and was an investigator and speaker for Connetics, receiving grants and honoraria; was an investigator and speaker for Xtrac and VGV and has received honoraria from Synta for another function. Dr. Van Voorhees’ spouse is an employee with Merck receiving a salary, stock, and stock options.
Craig A. Elmets, MD: Dr Elmets has served on the Advisory Board and was investigator for Amgen and Abbott Labs, receiving grants and honoraria; was consultant for Astellas, receiving honoraria; and was an investigator for Genentech and Connetics, receiving grants.

Craig L. Leonardi, MD: Dr Leonardi served on the Advisory Board and was consultant, investigator, and speaker for Abbott Labs, Amgen, Centocor, and Genentech receiving honoraria, other financial benefits, and grants for Amgen and Genentech; was speaker for Warner Chillcott, receiving honoraria; was on the Advisory Board and was an investigator for Serano, receiving honoraria and other financial benefit; was an investigator for Astellas, Biogen, Bristol Myers, Allergan, Fujisawa, CombinatorRx, and Vitae, receiving other financial benefit.

Karl R. Beutner, MD, PhD: Chair Clinical Research Committee. Dr Beutner was an employee of Anacor, receiving salary, stock, and stock options; and had other relationships and received stocks from Dow Pharmaceutical Sciences.

Reva Bhushan, PhD: Dr Bhushan has no relevant conflicts of interest to disclose.

Alan Menter, MD: Chair Psoriasis Work Group. Dr Menter served on the Advisory Board and was a consultant, investigator and speaker for Abbott Labs, Amgen, and Centocor, receiving grants and honoraria; served on the Advisory Board and was an investigator and consultant for Cephalon and UCB, receiving grants and honoraria; was a consultant, investigator, and speaker for Warner Chillcott and Wyeth, receiving honoraria; served on the Advisory Board and was an investigator for Galderma and Genentech, receiving grants and honoraria; was a consultant and investigator for Allergan and Astellas, receiving grants and honoraria; was an investigator for Collagenex, CombinatorRx, Dow, Ferndale, Leo, Medicis, Photocure, Pierre Fabre, 3M Pharmaceuticals, and XOMA receiving grants; and was an investigator for Connetics, receiving grants and honorarium.

REFERENCES


